Biotechnology company Bristol Myers Squibb (NYSE: BMY) Friday reported higher revenues and net profit for the second quarter of 2024. Net income
BMY Earnings: Bristol-Myers Squibb reports higher Q2 revenue and profit
![Bristol-Myers Squibb Company Q2 2024 earnings infographic](https://cdn.news.alphastreet.com/wp-content/uploads/2024/07/Bristol-Myers-Squibb-Company-Q2-2024-earnings-infographic-700x400.jpg)
Biotechnology company Bristol Myers Squibb (NYSE: BMY) Friday reported higher revenues and net profit for the second quarter of 2024. Net income
There has been a strong uptick in IPO activity this year compared to 2023 when the market witnessed a slowdown. In the
Technology and healthcare companies are continuing to dominate the IPO market, which is witnessing a significant increase in activity compared to 2023.
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a new-generation biotechnology firm that works to accelerate the development of new therapies by partnering with
The Cigna Group (NYSE: CI), a healthcare company focused on medical insurance and related services, Thursday reported a sharp increase in revenues for
Moderna, Inc. (NASDAQ: MRNA) reported a net loss for the first quarter of 2024 when the biotechnology company's revenues declined sharply. Q1
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the first quarter of 2024, aided
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Wednesday reported an increase in adjusted profit for the first quarter of 2024, despite a decline
Abbott Laboratories (NYSE: ABT) reported its first quarter 2024 earnings results today. Total sales increased 2.2% year-over-year to $10 billion. Organic sales growth
Femasys Inc. (NASDAQ: FEMY) is a healthcare company that develops women's reproductive health solutions using state-of-the-art technology. The company’s portfolio includes minimally
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of
Biotechnology company Moderna, Inc. (NASDAQ: MRNA) reported a sharp decline in revenues and earnings for the fourth quarter of 2023. Net income
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biotechnology company that works with leading researchers and institutions to accelerate the development of new
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the fourth quarter of 2023. Total
Eli Lilly and Company (NYSE: LLY) on Tuesday reported double-digit growth in revenues and adjusted earnings for the fourth quarter of 2023.
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced fourth-quarter 2023 financial results, reporting lower revenues and net income. The company reported
Pharmaceutical company Eli Lilly and Company (NYSE: LLY) is preparing to report fourth-quarter earnings. In recent years, the drugmaker successfully diversified beyond
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp fall in adjusted earnings for the fourth quarter of 2023, despite
Abbott Laboratories (NYSE: ABT), a diversified healthcare services company, Wednesday reported its fourth quarter 2023 financial results. Net income, excluding special items, increased
Walgreens Boots Alliance, Inc. (NASDAQ: WBA) on Thursday reported stronger-than-expected earnings and revenues for the first quarter of 2024. Net profit, on
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said that new findings, co-authored by the company’s scientific co-founder Jack A. Elias